Menu

Our Research

Our Research Partner ccTDI

Artisan Biopharma is wholly-owned by The Children’s Cancer Therapy Development Institute, www.cc-tdi.org, a 501c3 nonprofit. Artisan will license intellectual property from cc-TDI as well as other research entities. Artisan will also in-license drugs from pharmaceutical companies for repurposing - all informed by the research at cc-TDI and elsewhere.

 

The Children’s Cancer Therapy Development Institute is a unique 501c3 non-profit organization focused on the ‘preclinical gap’ in childhood cancer research.

cc-TDI was built to complement the Children’s Oncology Group & related clinical trial networks while synergizing with both academic laboratories and pharma R&D laboratories.

Our mission is to bridge scientific discovery and the initiation of clinical trials. We provide evidence-based testing for a selection of new drugs to be used in childhood cancer clinical trials, thus seeding pediatric Phase I and II trials. This concept was emphasized in the Institute of Medicine Report, Making Better Drugs for Children with Cancer in 2005

Our deliverables are not only peer-reviewed publications and NIH-funded grant funding, but also the initiation of national cooperative group trials. In our first 33 months, we delivered 2 drugs from our Nature Medicine, Genes&Development and ScienceSignaling publications into clinical trials for childhood brain tumors (NCT0171745) and sarcomas (NCT02780804, with a follow-on phase II concept in development, plus European study NCT03838042).

Bloom Syndrome treatments, preventions and cures

  • Recent reports estimate that up to 10% of pediatric cancer patients carry a germline cancer predisposition mutation, and there are more than 50 syndromes that can lead to cancer predisposition. View Source
  • DNA Instability Syndromes in particular pose a challenge to effective treatment, as standard chemotherapy regimens have been found to lead to secondary malignancies, toxicity, and poor outcomes. This has been seen in Bloom syndrome, an ultra-rare syndrome that leads to the development of all cancer types seen in normal populations, but at much younger ages. View Source
  • We are exploring the development of effective chemo-preventative agents and targeted cancer therapies for persons with Bloom syndrome.

Every great team gets stronger with each member.

Please join ours. Reach out and a team member will be in touch soon.

CONTACT US